Literature DB >> 9184663

Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration.

C Bergeron1, M S Pollanen, L Weyer, A E Lang.   

Abstract

We report 3 patients with progressive supranuclear palsy (PSP) who developed limb apraxia, focal dystonia, and arm levitation late in the course of the disease. Neuropathological examination revealed cortical degeneration in addition to the characteristic pathological findings of PSP. Semiquantitative comparative histological and immunohistological studies of the neocortex of these patients as well as 5 cases of classical PSP and 4 cases of cortical-basal ganglionic degeneration (CBGD) revealed a distinctive form of cortical degeneration in PSP. The cortical degeneration was often circumscribed and confined to premotor and motor cortex. It was characterized by neuronal loss and gliosis. Swollen neurons were only rarely observed in neocortex of PSP cases in contrast with CBGD, where they were abundant. Neuronal and glial tau as well as tau immunoreactive threads were seen in both PSP and CBGD, but were more abundant in CBGD. The appearance of tau reactive astrocytes also differed in both disorders; tufted astrocytes were seen exclusively in PSP, while typical annular astrocytic plaques were confined to CBGD. These observations indicate that cortical degeneration occurs in PSP and may be associated with atypical clinical manifestations that lead to diagnostic difficulties.

Entities:  

Mesh:

Year:  1997        PMID: 9184663

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  10 in total

1.  Corticobasal Degeneration.

Authors:  Panida Piboolnurak; Cheryl H. Waters
Journal:  Curr Treat Options Neurol       Date:  2003-03       Impact factor: 3.598

2.  The relationship between clinical and pathological variables in Richardson's syndrome.

Authors:  Emma C Schofield; John R Hodges; Thomas H Bak; John H Xuereb; Glenda M Halliday
Journal:  J Neurol       Date:  2011-08-12       Impact factor: 4.849

3.  Orofacial apraxia in corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy and Parkinson's disease.

Authors:  Canan Ozsancak; Pascal Auzou; Kathy Dujardin; Niall Quinn; Alain Destée
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

Review 4.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  Progressive supranuclear palsy.

Authors:  K Tawana; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

6.  Progressive supranuclear palsy (PSP): a quantitative study of the pathological changes in cortical and subcortical regions of eight cases.

Authors:  R A Armstrong; P L Lantos; N J Cairns
Journal:  J Neural Transm (Vienna)       Date:  2007-08-07       Impact factor: 3.575

7.  Neuropsychiatric features of corticobasal degeneration.

Authors:  I Litvan; J L Cummings; M Mega
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

8.  Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD.

Authors:  Astrid Sydow; Katja Hochgräfe; Stefanie Könen; Daniela Cadinu; Dorthe Matenia; Olga Petrova; Maria Joseph; Frank Johannes Dennissen; Eva-Maria Mandelkow
Journal:  Acta Neuropathol Commun       Date:  2016-02-25       Impact factor: 7.801

Review 9.  Neurotrophic factors in Alzheimer's disease: role of axonal transport.

Authors:  K Schindowski; K Belarbi; L Buée
Journal:  Genes Brain Behav       Date:  2008-02       Impact factor: 3.449

10.  Aberrant role of ALK in tau proteinopathy through autophagosomal dysregulation.

Authors:  Jisu Park; Hyunwoo Choi; Young Doo Kim; Seo-Hyun Kim; Youbin Kim; Youngdae Gwon; Dong Young Lee; Sung-Hye Park; Won Do Heo; Yong-Keun Jung
Journal:  Mol Psychiatry       Date:  2021-01-15       Impact factor: 15.992

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.